Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis

Antonello Nicolini, Federica Cardini, Norma Landucci, Sergio Lanata, Maura Ferrari-Bravo, Cornelius Barlascini, Antonello Nicolini, Federica Cardini, Norma Landucci, Sergio Lanata, Maura Ferrari-Bravo, Cornelius Barlascini

Abstract

Background: High-frequency airway clearance (HFCWC) assist devices generate either positive or negative trans-respiratory pressure excursions to produce high-frequency, small-volume oscillations in the airways.HFCWC can lead to changes in volume of 15-57 ml and in flow up to 1.6 L/s, which generate minimal coughing to mobilize secretions. The typical treatment lasts 20-30 minutes, and consists of short periods of compression at different frequencies, separated by coughing.The aim of this study was to find the more efficacious treatment in patients with bronchiectasis: traditional techniques of chest physiotherapy (CPT) versus high frequency oscillation of the chest wall in patients with bronchiectasis.

Methods: 37 patients were enrolled. Seven of them were excluded. Computer randomization divided the patients into three groups: - 10 patients treated with HFCWO by using the Vest® Airway Clearance System; - 10 patients treated with traditional techniques of air way clearance (PEP bottle, PEP mask, ELTGOL, vibratory positive expiratory pressure); - 10 patients received medical therapy only (control group). To be eligible for enrollment, participants had to be between 18 and 85 years old and have a diagnosis of bronchiectasis, confirmed on high resolution computed tomography.

Exclusion criteria: lack of informed consent, signs of exacerbation, cystic fibrosis. Before the treatment, each patient had blood tests, sputum volume and cell count, pulmonary function tests and on the quality of life inventories (MMRC, CAT, BCSS). The results were processed through the covariance analysis, performed with the R-Project statistical program. It has been considered a positive result p <005.

Results: Both treatments (traditional CPT and HFCWO) showed a significant improvement in some biochemical and functional respiratory tests as well as in the quality of life compared to the control group. The use of HFCWO compared to CPT also produced a significant improvement in blood inflammation parameter C-RP (p ≤0.019), parameters of lung functionality associated with bronchial obstruction (FVC, FEV1) (p ≤0.006 and p ≤0.001), and in the dyspnea. Improvement in quality of life scales was noted. (BCSS, CAT) (both p ≤0.001). No significant changes of total cell counts in sputum samples were observed in the two groups. In the HFCWO group a significant reduction of neutrophils percentage (p≤0.002) and a significant increase of macrophages percentage (p ≤0.012).

Conclusions: The HFCWO technique provides an improvement both in pulmonary function and quality of life related parameters in patients with chronic hypersecretive disease. Since those patients need daily airway clearance, this treatment should be included among the principal options in chest physiotherapy. The study was registered as ChiCTR-TRC-12002134 at http://www.chictr.org.

Figures

Figure 1
Figure 1
Patients flow.
Figure 2
Figure 2
Dot-plot that shows BCSS score and CAT score change-values before and after treatment in HFCWO and CPT groups.
Figure 3
Figure 3
Dop-plot that shows FVC and FEV1 change values (ml) before and after treatment in HFCWO and CPT groups.

References

    1. Barker AF. Bronchiectasis. N Engl J Med. 2002;346:1383–1393. doi: 10.1056/NEJMra012519.
    1. Eyuboglu FO, Ugurlu AO, Habesoglu MA. Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis. Ann Thor Med. 2011;6(3):131–136. doi: 10.4103/1817-1737.82443.
    1. Alzeer AH, Al-Mobeirek AF, Al-Otair HA, Elzamzamy UA, Shaffy AS, Joherjy IA. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest. 2008;133:468–473. doi: 10.1378/chest.07-1639.
    1. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in adult bronchiectasis patients. COPD. 2005;2:27–34. doi: 10.1081/COPD-200050685.
    1. Alzeer AH, Masood M, Basha SJ, Shaik SA. Survival of bronchiectatic patients with respiratory failure in ICU. BMC Pulm Med. 2007;7:17. doi: 10.1186/1471-2466-7-17.
    1. Paneroni M, Clini E, Simonelli C, Bianchi L, Degli Antoni F, Vitacca M. Safety and efficacy of short-term intrapulmonary percussive ventilation in patients with bronchiectasis. Resp Care. 2011;56(7):984–988. doi: 10.4187/respcare.01098.
    1. Martinez Garcia MA, Carro LM, Serra PC. Treatment of non-cystic fibrosis bronchiectasis. Arch Broncopneumol. 2011;47(12):599–609.
    1. Ilowite J, Spiegler P, Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr opin infect Dis. 2008;21(2):163–167. doi: 10.1097/QCO.0b013e3282f4f237.
    1. O’Donnel AE. Bronchiectasis. Chest. 2008;134(4):815–823. doi: 10.1378/chest.08-0776.
    1. Metersky ML. New treatment options for bronchiectasis. Ther Adv Respir Dis. 2010;4(2):93–99. doi: 10.1177/1753465810366858.
    1. Daviskas E, Anderson SD, Gomes K, Briffa P, Cochrane B, Chan HK. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis:effect on lung function, health status and sputum. Respirology. 2005;10:46–56. doi: 10.1111/j.1440-1843.2005.00659.x.
    1. Yalcin E, Kiper N, Ozcelik U, Dogru D, Firat P, Sahin A. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm ther. 2006;31:49–55. doi: 10.1111/j.1365-2710.2006.00708.x.
    1. Nogrady SG, Evans WV, Davies BH. Reversibility of airways obstructions in bronchiectasis. Thorax. 1978;33:635–637. doi: 10.1136/thx.33.5.635.
    1. Pryor JA. Physical therapy for adults with bronchiectasis. Clin Pulm Med. 2004;11:201–209. doi: 10.1097/01.cpm.0000132887.59914.4b.
    1. McCool FD, Rosen MJ. Non pharmacological airway clearance therapies.ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):S250–S259. doi: 10.1378/chest.129.1_suppl.250S.
    1. Eaton T, Young P, Zeng I, Kolbe J. A randomized evaluation of the acute efficacy, acceptability and tolerability of flutter and active cycle of breathing with and without postural drainage in non-cystic fibrotic bronchiectasis. Chron Resp Dis. 2007;2007(4):23–30.
    1. Mutalithas K, Watkin G, Willing B, Wardlaw A, Pavord ID, Birring SS. Improvement in health status following bronchopulmonary hygiene physical therapy in patients with bronchiectasis. Resp Med. 2008;102(8):1140–1144. doi: 10.1016/j.rmed.2008.03.011.
    1. Patterson JE, Bradley JM, Elborn JS. Airways clearance in bronchiectasis:a randomized crossover trial of active cycle of breathing techniques (incorporating Postural drainage and vibration) versus test of incremental respiratory endurance. Chronic Resp Dis. 2004;1(3):127–130. doi: 10.1191/1479972304cd034oa.
    1. Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R. British Thoracic Society Physiotherapy guideline development Group. Guidelines for the physiotherapy management of the adult,medical,spontaneously breathing patients. Thorax. 2009;64(1):1–51. doi: 10.1136/thx.2008.110726.
    1. Rowe SM, Clancy JP. Advances in cystic fibrosis therapies. Curr Opin Pediatr. 2006;18:604–613. doi: 10.1097/MOP.0b013e3280109b90.
    1. Osman LP, Roughton M, Hodson ME, Pryor JA. Short-term comparative study of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis. Thorax. 2010;65:196–200. doi: 10.1136/thx.2008.111492.
    1. Chakravorty I, Chahal K, Austin G. A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion. Int j COPD. 2011;6:693–699.
    1. Mahajan AK, Dietta GB, Hatipoglu U, Bilderback S, Ridge A, Walker Harris V. High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial. Resp Res. 2011;12:120. doi: 10.1186/1465-9921-12-120.
    1. Guimares FS, Moco VJR, Menezes SLS, Diaz CM, Alles REB, Lopes AJ. Effects of Eltgoland flutter VRPI on the dynamic and static pulmonary volumes and on the other secretion clearance of patients with bronchiectasis. Rev Bras Fisioter. 2012;16(2):108–113. doi: 10.1590/S1413-35552012005000016.
    1. West K, Wallen M, Follett J. Acapella vs. PEP mask therapy: a randomised trial in children with cystic fibrosis during respiratory exacerbation. Physiother Theory Pract. 2010;26(3):143–149. doi: 10.3109/09593980903015268.
    1. Sehling M, Ohberg F, Johansson MS, Winso O. Physiological responses to positive expiratory pressure breathing:a comparison of the PEP bottle and the PEP mask. Resp Care. 2007;52(8):1000–1005.
    1. Santos AP, Guimarães RC, De Carvalho EM, Gastaldi AC. Mechanical behaviors of Flutter VRP1, Shaker, and Acapella Devices. Resp Care. 2013;58(2):298–304. in press.
    1. Leidy NK, Rennard S, Schmier J, Jones K, Goldman M. The breathlessness,cough,and sputum scale.The development of empirically based guidelines for interpretation. Chest. 2182;124:2182–2191.
    1. Dodd JW, Hogg L, Nolan J, Jefford H, Grant A, Lord VM. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre prospective study. Thorax. 2011;66(5):425–429. doi: 10.1136/thx.2010.156372.
    1. Lee BY, Lee S, Lee JS, Song JW, Lee SD, Jang SH. Validity and reliability of CAT and Dyspnea-12 in bronchiectasis and tubercolous destroyed lung. Tuberc Respir Dis. 2012;72:467–474. doi: 10.4046/trd.2012.72.6.467.
    1. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D. Indices of airway inflammation in induced sputum:reproducibility and validity of cell and fluid-phase measurement. AmJ Resp Crit Care Med. 1996;154:308–317. doi: 10.1164/ajrccm.154.2.8756799.
    1. Moritz P, Marquez Steidle LJ, Felisbino MB, Kleveston T, Pizzichini MM, Pizzichini E. Determination of the inflammatory component of airway diseases by induced sputum cell counts: use in clinical practice. J Bras Pneumolo. 2008;34(11):913–921.
    1. VareKojis SM, Douce FH, Flucke RL, Filburn DA, Tice JS, McCoy KS. A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients. Resp Care. 2003;48:24–28.
    1. Miller MR, Hankinson J, Brusaco V, Burgos F, Casaburi R, Coates A, Crapo R. Standadization of spirometry. Eur Resp J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805.
    1. Pryor JA. Physiotherapy for airway clearance in adults. Eur Resp J. 1999;14:1418–1424. doi: 10.1183/09031936.99.14614189.
    1. Anderson CA, Palmer CA, Ney AL, Becker B, Schaffel B, Quickel RR. Evaluation of the Safety of high-frequency chest wall oscillation (HFCWO) therapy in blunt thoracic patients. J trauma Manag Outcomes. 2008;2:8–14. doi: 10.1186/1752-2897-2-8.
    1. Braveman J, Nozzarella M. High-frequency chest compression advanced therapy for obstructive lung disease. Resp Therapy. 2007;2:48–51.
    1. Warwick WJ, Hansen LG. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr Pulmonol. 1991;11:265–271. doi: 10.1002/ppul.1950110314.
    1. Kempainen RR, Milla C, Dunitz J, Savik K, Hazelwood A, Williams C. Comparison of settings used for high-frequency chest wall compression in cystic fibrosis. Respir Care. 2010;55:695–701.
    1. Darbee JC, Kanga JF, OHtake PJ. Physiologic evidence for high-frequency chest wall oscillation and positive expiratory pressure breathing in hospitalized subjects with cystic fibrosis. Phys Ther. 2005;85:1278–1289.
    1. Fainardi V, Longo F, Faverzani S, Tripodi MC, Chetta A, Pisi G. Short-term effects of high- Frequency chest compression and positive expiratory pressure in patients with cystic fibrosis. J Clin Med Rese. 2011;3(6):279–284.
    1. Arens R, Gozal A, Omlin KJ, Vega J, Boyd KP, Keens G. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Resp Crit Care Med. 1994;150:1154–1157. doi: 10.1164/ajrccm.150.4.7921452.
    1. Kempainen RR, Williams CB, Hazelwood A, Rubin BK, Milla CE. Comparison of high-Frequency chest wall oscillation with differing waveforms for airway clearance in cystic Fibrosis. Chest. 2007;132:1227–1232. doi: 10.1378/chest.07-1078.
    1. Isabey D, Harf A, Chang HK. Alveolar ventilation during high-frequency oscillation: core dead space concept. J Appl Physiol. 1984;56:700–707.
    1. Jones RL, Lester RT, Brown NE. Effects of high-frequency chest compression on respiratory system mechanics in normal subjects and cystic fibrosis patients. Can Resp J. 1995;2:40–46.
    1. Bradley JM. High frequency chest wall oscillation in cystic fibrosis. Thorax. 2010;65(3):189–190. doi: 10.1136/thx.2009.122663.
    1. Oermann CM, Sockrider MM, Giles D, Sontag MK, Accuso FJ, Castile RG. Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis:a pilot study. Pediatr Pulmonol. 2001;32:372–377. doi: 10.1002/ppul.1146.
    1. Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB. Induced sputum cellularity, Reference values and distribution in normal volunterees. Am J Resp Crit Care Med. 2000;162:1172–1174. doi: 10.1164/ajrccm.162.3.9908057.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren